In-vitro evaluation of cefpodoxime

S. Valentini, G. Coratza, G. M. Rossolini, O. Massidda, G. Satta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In-vitro antimicrobial activity of cefpodoxime was evaluated against several microbial species by both conventional tests and additional parameters which take into consideration some of the conditions likely to be encountered in infected tissues. MICs for 414 recent clinical isolates, including staphylococci, streptococci, Haemophilus influenzae, Moraxella catarrhalis, several Enterobacteriaceae, Aeromonas hydrophila and Campylobacter jejuni were determined. MIC values overall were similar to those observed for strains from other geographical areas. Inhibition of growth by cefpodoxime was virtually unaffected by the inoculum size, even using bacterial populations as large as 109 cfu of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, H. influenzae, β-lactamase-negative M catarrhalis, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Growth in the presence of human serum as the only source of nutrients did not significantly affect the inhibition exerted by cefpodoxime, even against large bacterial populations of S. aureus, S. pneumoniae, E. coli, and K. pneumoniae. For K. pneumoniae, E. coli, P. mirabilis and β-lactamase-negative M. catarrhalis it was also found that sub-MIC concentrations of cefpodoxime were still able to inhibit the majority of cells in microbial populations as large as 109 cfu. Evaluation of bactericidal activity demonstrated that cefpodoxime concentrations comparable to those achievable in plasma or in the respiratory tract were able to kill rapidly large bacterial populations of S. pneumoniae and S. pyogenes The bactericidal activity was apparently lower against M. catarrhalis, H. influenzae, S. aureus, E. coli, and K. pneumoniae.

Original languageEnglish
Pages (from-to)495-508
Number of pages14
JournalJournal of Antimicrobial Chemotherapy
Volume33
Issue number3
Publication statusPublished - 1994

Fingerprint

cefpodoxime
Escherichia coli
Escherichia Coli
Klebsiella pneumoniae
Influenza
Moraxella (Branhamella) catarrhalis
Haemophilus influenzae
Evaluation
Proteus mirabilis
Streptococcus pyogenes
Streptococcus pneumoniae
Streptococcus
Population
Staphylococcus aureus
Staphylococcal Pneumonia
Aeromonas hydrophila
Nutrients
Campylobacter jejuni
Enterobacteriaceae
Growth

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Valentini, S., Coratza, G., Rossolini, G. M., Massidda, O., & Satta, G. (1994). In-vitro evaluation of cefpodoxime. Journal of Antimicrobial Chemotherapy, 33(3), 495-508.

In-vitro evaluation of cefpodoxime. / Valentini, S.; Coratza, G.; Rossolini, G. M.; Massidda, O.; Satta, G.

In: Journal of Antimicrobial Chemotherapy, Vol. 33, No. 3, 1994, p. 495-508.

Research output: Contribution to journalArticle

Valentini, S, Coratza, G, Rossolini, GM, Massidda, O & Satta, G 1994, 'In-vitro evaluation of cefpodoxime', Journal of Antimicrobial Chemotherapy, vol. 33, no. 3, pp. 495-508.
Valentini S, Coratza G, Rossolini GM, Massidda O, Satta G. In-vitro evaluation of cefpodoxime. Journal of Antimicrobial Chemotherapy. 1994;33(3):495-508.
Valentini, S. ; Coratza, G. ; Rossolini, G. M. ; Massidda, O. ; Satta, G. / In-vitro evaluation of cefpodoxime. In: Journal of Antimicrobial Chemotherapy. 1994 ; Vol. 33, No. 3. pp. 495-508.
@article{14f72b59f08e4ea695ee50fd6dcb4144,
title = "In-vitro evaluation of cefpodoxime",
abstract = "In-vitro antimicrobial activity of cefpodoxime was evaluated against several microbial species by both conventional tests and additional parameters which take into consideration some of the conditions likely to be encountered in infected tissues. MICs for 414 recent clinical isolates, including staphylococci, streptococci, Haemophilus influenzae, Moraxella catarrhalis, several Enterobacteriaceae, Aeromonas hydrophila and Campylobacter jejuni were determined. MIC values overall were similar to those observed for strains from other geographical areas. Inhibition of growth by cefpodoxime was virtually unaffected by the inoculum size, even using bacterial populations as large as 109 cfu of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, H. influenzae, β-lactamase-negative M catarrhalis, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Growth in the presence of human serum as the only source of nutrients did not significantly affect the inhibition exerted by cefpodoxime, even against large bacterial populations of S. aureus, S. pneumoniae, E. coli, and K. pneumoniae. For K. pneumoniae, E. coli, P. mirabilis and β-lactamase-negative M. catarrhalis it was also found that sub-MIC concentrations of cefpodoxime were still able to inhibit the majority of cells in microbial populations as large as 109 cfu. Evaluation of bactericidal activity demonstrated that cefpodoxime concentrations comparable to those achievable in plasma or in the respiratory tract were able to kill rapidly large bacterial populations of S. pneumoniae and S. pyogenes The bactericidal activity was apparently lower against M. catarrhalis, H. influenzae, S. aureus, E. coli, and K. pneumoniae.",
author = "S. Valentini and G. Coratza and Rossolini, {G. M.} and O. Massidda and G. Satta",
year = "1994",
language = "English",
volume = "33",
pages = "495--508",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - In-vitro evaluation of cefpodoxime

AU - Valentini, S.

AU - Coratza, G.

AU - Rossolini, G. M.

AU - Massidda, O.

AU - Satta, G.

PY - 1994

Y1 - 1994

N2 - In-vitro antimicrobial activity of cefpodoxime was evaluated against several microbial species by both conventional tests and additional parameters which take into consideration some of the conditions likely to be encountered in infected tissues. MICs for 414 recent clinical isolates, including staphylococci, streptococci, Haemophilus influenzae, Moraxella catarrhalis, several Enterobacteriaceae, Aeromonas hydrophila and Campylobacter jejuni were determined. MIC values overall were similar to those observed for strains from other geographical areas. Inhibition of growth by cefpodoxime was virtually unaffected by the inoculum size, even using bacterial populations as large as 109 cfu of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, H. influenzae, β-lactamase-negative M catarrhalis, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Growth in the presence of human serum as the only source of nutrients did not significantly affect the inhibition exerted by cefpodoxime, even against large bacterial populations of S. aureus, S. pneumoniae, E. coli, and K. pneumoniae. For K. pneumoniae, E. coli, P. mirabilis and β-lactamase-negative M. catarrhalis it was also found that sub-MIC concentrations of cefpodoxime were still able to inhibit the majority of cells in microbial populations as large as 109 cfu. Evaluation of bactericidal activity demonstrated that cefpodoxime concentrations comparable to those achievable in plasma or in the respiratory tract were able to kill rapidly large bacterial populations of S. pneumoniae and S. pyogenes The bactericidal activity was apparently lower against M. catarrhalis, H. influenzae, S. aureus, E. coli, and K. pneumoniae.

AB - In-vitro antimicrobial activity of cefpodoxime was evaluated against several microbial species by both conventional tests and additional parameters which take into consideration some of the conditions likely to be encountered in infected tissues. MICs for 414 recent clinical isolates, including staphylococci, streptococci, Haemophilus influenzae, Moraxella catarrhalis, several Enterobacteriaceae, Aeromonas hydrophila and Campylobacter jejuni were determined. MIC values overall were similar to those observed for strains from other geographical areas. Inhibition of growth by cefpodoxime was virtually unaffected by the inoculum size, even using bacterial populations as large as 109 cfu of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, H. influenzae, β-lactamase-negative M catarrhalis, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Growth in the presence of human serum as the only source of nutrients did not significantly affect the inhibition exerted by cefpodoxime, even against large bacterial populations of S. aureus, S. pneumoniae, E. coli, and K. pneumoniae. For K. pneumoniae, E. coli, P. mirabilis and β-lactamase-negative M. catarrhalis it was also found that sub-MIC concentrations of cefpodoxime were still able to inhibit the majority of cells in microbial populations as large as 109 cfu. Evaluation of bactericidal activity demonstrated that cefpodoxime concentrations comparable to those achievable in plasma or in the respiratory tract were able to kill rapidly large bacterial populations of S. pneumoniae and S. pyogenes The bactericidal activity was apparently lower against M. catarrhalis, H. influenzae, S. aureus, E. coli, and K. pneumoniae.

UR - http://www.scopus.com/inward/record.url?scp=0028201444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028201444&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 495

EP - 508

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

ER -